Une thérapie de réécriture de base de haute précision démontre une efficacité durable, sans crises vaso-occlusives et un profil d'innocuité favorable dans le traitement de la drépanocytose

Data ReadoutpositiveCS-206Positive

AI Analysis

Summary

CorrectSequence Therapeutics reported positive 15-month follow-up data for CS-206, a base editing therapy for sickle cell disease, demonstrating sustained efficacy without vaso-occlusive crises and a favorable safety profile.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

15-month follow-up data showing sustained efficacy, no vaso-occlusive crises, and favorable safety profile

Importance:7/10

Sentiment:

0.85

base editingsickle cell diseasegene therapyclinical data15-month follow-up

Read the original article

Published by PR Newswire Biotech on June 3, 2026 1:05 PM

Read Original